Alnylam Pharmaceuticals
ALNY
#555
Rank
A$61.19 B
Marketcap
A$461.44
Share price
-3.01%
Change (1 day)
9.35%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): A$2.66

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is A$2.60. In 2023 the company made an earnings per share (EPS) of A-$5.11 an increase over its 2022 EPS that were of A-$13.44.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$2.66
2023A-$5.11-62%
2022A-$13.4429.03%
2021A-$10.42-3.36%
2020A-$10.78-8.48%
2019A-$11.787.67%
2018A-$10.9439.74%
2017A-$7.8312.94%
2016A-$6.9338.84%
2015A-$4.99-32.88%
2014A-$7.44259.44%
2013A-$2.07-31.25%
2012A-$3.01

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
A$10.42 300.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$2.99 14.73%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$62.40 2,295.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A-$3.97-252.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A-$1.06-140.56%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A-$0.35-113.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$1.79-31.11%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
A$0.51-80.56%๐Ÿ‡บ๐Ÿ‡ธ USA